Moolec Science Sa (MLEC)

$0.89

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $0.85
    $0.89
    $0.89
    downward going graph

    4.48%

    Downside

    Day's Volatility :4.48%

    Upside

    0.0%

    downward going graph
  • $0.75
    $3.25
    $0.89
    downward going graph

    15.73%

    Downside

    52 Weeks Volatility :76.92%

    Upside

    72.62%

    downward going graph

Returns

PeriodMoolec Science SaIndex (Russel 2000)
3 Months
-17.05%
0.0%
6 Months
-26.64%
0.0%
1 Year
-69.71%
0.0%
3 Years
-90.25%
-20.6%

Highlights

Market Capitalization
33.7M
Book Value
$0.18
Earnings Per Share (EPS)
-0.16
Wall Street Target Price
6.0
Profit Margin
-150.28%
Operating Margin TTM
-96.78%
Return On Assets TTM
-27.72%
Return On Equity TTM
-82.56%
Revenue TTM
5.0M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-9.4M
Diluted Eps TTM
-0.16
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.19
EPS Estimate Next Year
-0.24
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Moolec Science Sa(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 574.16%

Current $0.89
Target $6.00

Technicals Summary

Sell

Neutral

Buy

Moolec Science Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Moolec Science Sa
Moolec Science Sa
-1.38%
-26.64%
-69.71%
-90.25%
-90.25%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.82%
7.63%
22.08%
84.17%
257.49%
Novo Nordisk A/s
Novo Nordisk A/s
-12.08%
-8.57%
27.88%
136.23%
343.21%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
7.18%
75.52%
50.82%
35.89%
250.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.21%
11.53%
27.71%
156.23%
163.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Moolec Science Sa
Moolec Science Sa
NA
NA
NA
-0.19
-0.83
-0.28
NA
0.18
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.42
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.7
38.7
1.75
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Moolec Science Sa
Moolec Science Sa
Buy
$33.7M
-90.25%
NA
-150.28%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.7B
257.49%
27.55
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$518.0B
343.21%
38.7
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.9B
250.13%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.3B
163.62%
32.84
-4.74%

Insights on Moolec Science Sa

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.8% return, outperforming this stock by 120.5%

Company Information

Organization
Moolec Science Sa
Employees
45
CEO
Mr. Gaston Paladini M.B.A.
Industry
Miscellaneous

FAQs